When practices submit price matches all SWON members benefit! Thanks to the watchful eyes of our members, SWON participating practices are driving down drug costs.
|
Lord of the Files
Visit the official blog for guests and subscribers of the Oncology Manager's Briefcase.
Click Here
|
|
| Contact Us
| Melissa Welch
Southwest Oncology Network
6921 Shoreview Drive
| |
|
|
Keep your Membership Current
If there are changes to your phone number, physical address, primary contact etc. or if your practice merges with another organization, please be sure to notify SWON.
|
|
 |
 |
|
|
Understanding the ASP Reimbursement Report
Each quarter, SWON prepares and distributes a report on CMS ASP reimbursement. The Q1 2011 report was distributed last week. The report's objective is to provide a straight ASP/ASP+6% reimbursement analysis of Oncology Supply invoice drug cost vs. CMS reimbursement. It is important to note that in addition to the invoice price vs. reimbursement breakdown, practices must calculate the 5% rebate on generics and any available manufacturer rebates when evaluating the net profit or loss on a particular drug.
For example, in the current report, Fusilev Levoleuco (Item #32424) is shown with a loss of $43.44 based on ASP+6% on ZED pricing terms. However, when the manufacturer rebate, available to SWON members, is factored in, the product has an approximate net profit of $9.22. Practices need to consult their particular payment terms and contract level with Oncology Supply/ION when calculating net price.
If you did not receive a copy of the ASP reimbursement report, click here to request a copy. The report will be sent electronically following verification of current SWON membership.
As always, SWON and your Oncology Supply and ION representatives are available for questions on pricing as well. |
|
|
Participate in a Test Market for Totect® Urgent Treatment Kit
Effective October 4, 2010, Topotarget is offering oncology infusion centers the opportunity to participate in a test market for Totect Urgent Treatment Kit. Test market participants will be eligible to purchase Totect from an authorized distributor at $6,500 and receive one replacement kit, should the kit expire before use. Totect has a shelf life of 24 months from the date of manufacturing. Product at authorized distributors currently has a shelf life of 16 to 19 months.
Totect (dexrazoxane for injection) is packaged in an Urgent Treatment Kit for single patient use and includes 10 viles of Totect powder 500mg each and 10 vials of Totect diluent 50mL each.
For more information, click here.
|
|
|
ASHP and other associations urge Congress to pass legislation that will ease drug shortages
Executives with the American Society of Health-System Pharmacists (ASHP) and other groups are urging Congress to pass federal legislation to ease drug shortages in the United States.
ASHP, along with representatives from the American Society of Anesthesiologies, the American Society of Clinical Oncoloy, and the American Hospital Association recently met with aides to Sen. Amy Klobuchar (D-Minn.) to discuss the key points that should be included in federal legislations.
Read More |
|
|
|
Q4 2010 rebates are scheduled to be distributed to eligible practices in mid February. Practices must have been current on all payments to Oncology Supply during the quarter to be eligible for the rebate.
Additionally, all SWON membership forms must be up to date. Forms that needed to be completed were mailed to affected practices in late December along with a report on the rebates paid to your practice during the last fiscal year. Be sure to complete any forms that were mailed to your practice by February 10 so we can mail your rebate out. If you are not sure whether your practice has forms outstanding, click here to request a review. |
|
|
|
Suggested Reading |
Overdosed America: The Broken Promise of Amerian Medicine (P.S.)
By John Abramson (as described on amazon.com)
Using the examples of Vioxx, Celebrex, cholesterol-lowering statin drugs, and anti-depressants, Overdosed America shows that at the heart of the current crisis in American medicine lies the commercialization of medical knowledge itself.
Drawing on his background in statistics, epidemiology, and health policy, John Abramson, M.D., reveals the ways in which the drug companies have misrepresented statistical evidence, misled doctors, and compromised our health. The good news is that the best scientific evidence shows that reclaiming responsibility for your own health is often far more effective than taking the latest blockbuster drug.
You-and your doctor-will be stunned by this unflinching exposé of American medicine.
For ordering information click here .
|
|
